

**VERQUVO
(vericiguat)**

Pre - PA Allowance

None

Prior-Approval Requirements

Age 18 years of age or older

Diagnosis

Patient must have the following:

Chronic heart failure

AND ALL of the following:

1. NYHA activity class II – IV
2. Systolic dysfunction with left ventricular ejection fraction < 45%
3. Heart failure hospitalization within the last 6 months **OR** use of outpatient IV diuretics for heart failure within the last 3 months
4. Prescribed by or recommended by a cardiologist
5. Patient is currently receiving optimal therapy for heart failure management (e.g., beta blocker, angiotensin-converting enzyme (ACE) inhibitor, angiotensin II receptor blocker (ARB), angiotensin receptor and neprilysin inhibitor (ARNI)
6. Used in combination with other heart failure therapies as tolerated (e.g., beta blocker, angiotensin-converting enzyme (ACE) inhibitor, angiotensin II receptor blocker (ARB), angiotensin receptor and neprilysin inhibitor (ARNI) and diuretics)
7. Patient has had an inadequate response, intolerance, or contraindication to a sodium-glucose cotransporter-2 (SGLT2) inhibitor
8. **NO** concurrent therapy with other soluble guanylate cyclase (sGC) stimulators (such as riociguat)
9. Females of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Verquvo and for 1 month after the final dose

Prior - Approval Limits

Quantity 100 tablets per 100 days

Duration 2 years

**VERQUVO
(vericiguat)**

Prior – Approval *Renewal* Requirements

Age 18 years of age or older

Diagnosis

Patient must have the following:

Chronic heart failure

AND ALL of the following:

1. Symptoms have improved or stabilized
2. Patient is currently receiving optimal therapy for heart failure management (e.g., beta blocker, angiotensin-converting enzyme (ACE) inhibitor, angiotensin II receptor blocker (ARB), angiotensin receptor and neprilysin inhibitor (ARNI)
3. Used in combination with other heart failure therapies as tolerated (e.g., beta blocker, angiotensin-converting enzyme (ACE) inhibitor, angiotensin II receptor blocker (ARB), angiotensin receptor and neprilysin inhibitor (ARNI) and diuretics)
4. **NO** concurrent therapy with other soluble guanylate cyclase (sGC) stimulators (such as riociguat)
5. Females of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Verquvo and for 1 month after the final dose

Prior - Approval *Renewal* Limits

Same as above